Distinct non-ischemic myocardial late gadolinium enhancement lesions in patients with type 2 diabetes

Publikation: Bidrag til tidsskriftTidsskriftartikelfagfællebedømt

Standard

Distinct non-ischemic myocardial late gadolinium enhancement lesions in patients with type 2 diabetes. / Bojer, Annemie Stege; Sørensen, Martin Heyn; Vejlstrup, Niels; Goetze, Jens P.; Gæde, Peter; Madsen, Per Lav.

I: Cardiovascular Diabetology, Bind 19, 184, 2020.

Publikation: Bidrag til tidsskriftTidsskriftartikelfagfællebedømt

Harvard

Bojer, AS, Sørensen, MH, Vejlstrup, N, Goetze, JP, Gæde, P & Madsen, PL 2020, 'Distinct non-ischemic myocardial late gadolinium enhancement lesions in patients with type 2 diabetes', Cardiovascular Diabetology, bind 19, 184. https://doi.org/10.1186/s12933-020-01160-y

APA

Bojer, A. S., Sørensen, M. H., Vejlstrup, N., Goetze, J. P., Gæde, P., & Madsen, P. L. (2020). Distinct non-ischemic myocardial late gadolinium enhancement lesions in patients with type 2 diabetes. Cardiovascular Diabetology, 19, [184]. https://doi.org/10.1186/s12933-020-01160-y

Vancouver

Bojer AS, Sørensen MH, Vejlstrup N, Goetze JP, Gæde P, Madsen PL. Distinct non-ischemic myocardial late gadolinium enhancement lesions in patients with type 2 diabetes. Cardiovascular Diabetology. 2020;19. 184. https://doi.org/10.1186/s12933-020-01160-y

Author

Bojer, Annemie Stege ; Sørensen, Martin Heyn ; Vejlstrup, Niels ; Goetze, Jens P. ; Gæde, Peter ; Madsen, Per Lav. / Distinct non-ischemic myocardial late gadolinium enhancement lesions in patients with type 2 diabetes. I: Cardiovascular Diabetology. 2020 ; Bind 19.

Bibtex

@article{cf47d3eb77164f819fca8cf771c12c49,
title = "Distinct non-ischemic myocardial late gadolinium enhancement lesions in patients with type 2 diabetes",
abstract = "Background: Cardiovascular magnetic resonance imaging (CMR) have described localised non-ischemic late gadolinium enhancement (LGE) lesions of prognostic importance in various non-ischemic cardiomyopathies. Ischemic LGE lesions are prevalent in diabetes (DM), but non-ischemic LGE lesions have not previously been described or systematically studied in DM. Methods: 296 patients with type 2 DM (T2DM) and 25 sex-matched control subjects underwent echocardiography and CMR including adenosine-stress perfusion, T1-mapping and LGE. Results: 264 patients and all control subjects completed the CMR protocol. 78.4% of patients with T2DM had no LGE lesions; 11.0% had ischemic LGE lesions only; 9.5% had non-ischemic LGE lesions only; and 1.1% had both one ischemic and one non-ischemic lesion. The non-ischemic LGE lesions were situated mid-myocardial in the basal lateral or the basal inferolateral part of the left ventricle and the affected segments showed normal to high wall thickness and normal contraction. Patients with non-ischemic LGE lesions in comparison with patients without LGE lesions had increased myocardial mass (150 ± 34 vs. 133 ± 33 g, P = 0.02), average E/e{\textquoteright}(9.9 IQR8.7–12.6 vs. 8.8 IQR7.4–10.7, P = 0.04), left atrial maximal volume (102 IQR84.6–115.2 vs. 91 IQR75.2–100.0 mL, P = 0.049), NT-proBNP (8.9 IQR5.9–19.7 vs. 5.9 IQR5.9–10.1 µmol/L, P = 0.02) and high-sensitive troponin (15.6 IQR13.0–26.1 vs. 13.0 IQR13.0–14.6 ng/L, P = 0.007) and a higher prevalence of retinopathy (48 vs. 25%, P = 0.009) and autonomic neuropathy (52 vs. 30.5%, P = 0.005). Conclusion: A specific LGE pattern with lesions in the basal lateral or the basal inferolateral part of the left ventricle was found in patients with type 2 diabetes. Trial registrationhttps://www.clinicaltrials.gov. Unique identifier: NCT02684331.",
keywords = "Cardiovascular magnetic resonance imaging (MRI), Diabetes complications, Diabetes type 2, Late gadolinium enhancement, Risk factors",
author = "Bojer, {Annemie Stege} and S{\o}rensen, {Martin Heyn} and Niels Vejlstrup and Goetze, {Jens P.} and Peter G{\ae}de and Madsen, {Per Lav}",
year = "2020",
doi = "10.1186/s12933-020-01160-y",
language = "English",
volume = "19",
journal = "Cardiovascular Diabetology",
issn = "1475-2840",
publisher = "BioMed Central Ltd.",

}

RIS

TY - JOUR

T1 - Distinct non-ischemic myocardial late gadolinium enhancement lesions in patients with type 2 diabetes

AU - Bojer, Annemie Stege

AU - Sørensen, Martin Heyn

AU - Vejlstrup, Niels

AU - Goetze, Jens P.

AU - Gæde, Peter

AU - Madsen, Per Lav

PY - 2020

Y1 - 2020

N2 - Background: Cardiovascular magnetic resonance imaging (CMR) have described localised non-ischemic late gadolinium enhancement (LGE) lesions of prognostic importance in various non-ischemic cardiomyopathies. Ischemic LGE lesions are prevalent in diabetes (DM), but non-ischemic LGE lesions have not previously been described or systematically studied in DM. Methods: 296 patients with type 2 DM (T2DM) and 25 sex-matched control subjects underwent echocardiography and CMR including adenosine-stress perfusion, T1-mapping and LGE. Results: 264 patients and all control subjects completed the CMR protocol. 78.4% of patients with T2DM had no LGE lesions; 11.0% had ischemic LGE lesions only; 9.5% had non-ischemic LGE lesions only; and 1.1% had both one ischemic and one non-ischemic lesion. The non-ischemic LGE lesions were situated mid-myocardial in the basal lateral or the basal inferolateral part of the left ventricle and the affected segments showed normal to high wall thickness and normal contraction. Patients with non-ischemic LGE lesions in comparison with patients without LGE lesions had increased myocardial mass (150 ± 34 vs. 133 ± 33 g, P = 0.02), average E/e’(9.9 IQR8.7–12.6 vs. 8.8 IQR7.4–10.7, P = 0.04), left atrial maximal volume (102 IQR84.6–115.2 vs. 91 IQR75.2–100.0 mL, P = 0.049), NT-proBNP (8.9 IQR5.9–19.7 vs. 5.9 IQR5.9–10.1 µmol/L, P = 0.02) and high-sensitive troponin (15.6 IQR13.0–26.1 vs. 13.0 IQR13.0–14.6 ng/L, P = 0.007) and a higher prevalence of retinopathy (48 vs. 25%, P = 0.009) and autonomic neuropathy (52 vs. 30.5%, P = 0.005). Conclusion: A specific LGE pattern with lesions in the basal lateral or the basal inferolateral part of the left ventricle was found in patients with type 2 diabetes. Trial registrationhttps://www.clinicaltrials.gov. Unique identifier: NCT02684331.

AB - Background: Cardiovascular magnetic resonance imaging (CMR) have described localised non-ischemic late gadolinium enhancement (LGE) lesions of prognostic importance in various non-ischemic cardiomyopathies. Ischemic LGE lesions are prevalent in diabetes (DM), but non-ischemic LGE lesions have not previously been described or systematically studied in DM. Methods: 296 patients with type 2 DM (T2DM) and 25 sex-matched control subjects underwent echocardiography and CMR including adenosine-stress perfusion, T1-mapping and LGE. Results: 264 patients and all control subjects completed the CMR protocol. 78.4% of patients with T2DM had no LGE lesions; 11.0% had ischemic LGE lesions only; 9.5% had non-ischemic LGE lesions only; and 1.1% had both one ischemic and one non-ischemic lesion. The non-ischemic LGE lesions were situated mid-myocardial in the basal lateral or the basal inferolateral part of the left ventricle and the affected segments showed normal to high wall thickness and normal contraction. Patients with non-ischemic LGE lesions in comparison with patients without LGE lesions had increased myocardial mass (150 ± 34 vs. 133 ± 33 g, P = 0.02), average E/e’(9.9 IQR8.7–12.6 vs. 8.8 IQR7.4–10.7, P = 0.04), left atrial maximal volume (102 IQR84.6–115.2 vs. 91 IQR75.2–100.0 mL, P = 0.049), NT-proBNP (8.9 IQR5.9–19.7 vs. 5.9 IQR5.9–10.1 µmol/L, P = 0.02) and high-sensitive troponin (15.6 IQR13.0–26.1 vs. 13.0 IQR13.0–14.6 ng/L, P = 0.007) and a higher prevalence of retinopathy (48 vs. 25%, P = 0.009) and autonomic neuropathy (52 vs. 30.5%, P = 0.005). Conclusion: A specific LGE pattern with lesions in the basal lateral or the basal inferolateral part of the left ventricle was found in patients with type 2 diabetes. Trial registrationhttps://www.clinicaltrials.gov. Unique identifier: NCT02684331.

KW - Cardiovascular magnetic resonance imaging (MRI)

KW - Diabetes complications

KW - Diabetes type 2

KW - Late gadolinium enhancement

KW - Risk factors

U2 - 10.1186/s12933-020-01160-y

DO - 10.1186/s12933-020-01160-y

M3 - Journal article

C2 - 33092588

AN - SCOPUS:85093836470

VL - 19

JO - Cardiovascular Diabetology

JF - Cardiovascular Diabetology

SN - 1475-2840

M1 - 184

ER -

ID: 250966203